BrainStorm Therapeutics, a human organoid-and-AI CNS discovery company, won a Seed-Stage Start-Up Stadium award for its use of patient-derived brain organoids to generate translational biological data for AI-driven phenotypic drug discovery. The company highlighted lead work in CDKL5 deficiency disorder and discovery programs in Parkinson’s and Alzheimer’s disease. The company’s platform includes regionally defined organoids with interacting neural cell types and functional synaptic networks. BrainStorm also referenced progress from organoid screening to an FDA-cleared IND for a Phase 2 trial. The award and described workflow reflect how neuroscience start-ups are trying to close a common gap in CNS translation: aligning machine learning with robust human biology rather than relying solely on animal models.